Joseph Stringer
Stock Analyst at Needham
(2.10)
# 2,733
Out of 4,829 analysts
312
Total ratings
37.18%
Success rate
-7.28%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Joseph Stringer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| APLS Apellis Pharmaceuticals | Maintains: Buy | $40 → $29 | $17.30 | +67.63% | 20 | May 7, 2025 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $66 → $72 | $57.38 | +25.48% | 24 | May 7, 2025 | |
| VRTX Vertex Pharmaceuticals | Reiterates: Hold | n/a | $424.99 | - | 6 | May 6, 2025 | |
| IONS Ionis Pharmaceuticals | Maintains: Buy | $60 → $55 | $32.30 | +70.31% | 21 | Apr 30, 2025 | |
| GILD Gilead Sciences | Reiterates: Hold | n/a | $96.91 | - | 5 | Apr 25, 2025 | |
| PHAT Phathom Pharmaceuticals | Reiterates: Buy | $28 | $3.14 | +791.72% | 51 | Apr 21, 2025 | |
| CDTX Cidara Therapeutics | Reiterates: Buy | $35 | $18.63 | +87.87% | 10 | Apr 10, 2025 | |
| RNA Avidity Biosciences | Reiterates: Buy | $60 | $27.87 | +115.29% | 17 | Apr 9, 2025 | |
| STOK Stoke Therapeutics | Reiterates: Buy | $22 | $9.36 | +135.04% | 22 | Apr 9, 2025 | |
| ALNY Alnylam Pharmaceuticals | Reiterates: Buy | $320 | $251.15 | +27.41% | 21 | Apr 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $90 | $31.16 | +188.83% | 17 | Apr 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $15 | $1.15 | +1,204.35% | 18 | Apr 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $0.70 | - | 13 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $16 | $1.60 | +900.00% | 18 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $10 | $1.41 | +609.22% | 17 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $19 | $5.09 | +273.65% | 16 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $24.25 | - | 8 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $37 | $17.44 | +112.16% | 6 | Jan 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $18 | $8.98 | +100.45% | 2 | Aug 24, 2021 |
Apellis Pharmaceuticals
May 7, 2025
Maintains: Buy
Price Target: $40 → $29
Current: $17.30
Upside: +67.63%
Rhythm Pharmaceuticals
May 7, 2025
Maintains: Buy
Price Target: $66 → $72
Current: $57.38
Upside: +25.48%
Vertex Pharmaceuticals
May 6, 2025
Reiterates: Hold
Price Target: n/a
Current: $424.99
Upside: -
Ionis Pharmaceuticals
Apr 30, 2025
Maintains: Buy
Price Target: $60 → $55
Current: $32.30
Upside: +70.31%
Gilead Sciences
Apr 25, 2025
Reiterates: Hold
Price Target: n/a
Current: $96.91
Upside: -
Phathom Pharmaceuticals
Apr 21, 2025
Reiterates: Buy
Price Target: $28
Current: $3.14
Upside: +791.72%
Cidara Therapeutics
Apr 10, 2025
Reiterates: Buy
Price Target: $35
Current: $18.63
Upside: +87.87%
Avidity Biosciences
Apr 9, 2025
Reiterates: Buy
Price Target: $60
Current: $27.87
Upside: +115.29%
Stoke Therapeutics
Apr 9, 2025
Reiterates: Buy
Price Target: $22
Current: $9.36
Upside: +135.04%
Alnylam Pharmaceuticals
Apr 9, 2025
Reiterates: Buy
Price Target: $320
Current: $251.15
Upside: +27.41%
Apr 8, 2025
Reiterates: Buy
Price Target: $90
Current: $31.16
Upside: +188.83%
Apr 8, 2025
Reiterates: Buy
Price Target: $15
Current: $1.15
Upside: +1,204.35%
Mar 7, 2025
Reiterates: Hold
Price Target: n/a
Current: $0.70
Upside: -
Mar 4, 2025
Reiterates: Buy
Price Target: $16
Current: $1.60
Upside: +900.00%
Mar 4, 2025
Downgrades: Hold
Price Target: $10
Current: $1.41
Upside: +609.22%
Feb 27, 2025
Reiterates: Buy
Price Target: $19
Current: $5.09
Upside: +273.65%
Nov 8, 2024
Reiterates: Hold
Price Target: n/a
Current: $24.25
Upside: -
Jan 24, 2024
Upgrades: Buy
Price Target: $37
Current: $17.44
Upside: +112.16%
Aug 24, 2021
Maintains: Buy
Price Target: $32 → $18
Current: $8.98
Upside: +100.45%